Best Low-Float Stocks to Watch in 2026: Unlocking Volatility & Potential

Energy Vault Holdings Inc. (NRGV) is a company operating in the long-duration energy storage space, a sector that's garnering increasing attention as the world shifts towards renewable energy. What makes NRGV interesting from a low-float perspective is its 'relatively low float,' which contributes to its notable price fluctuations. Recently, on July 5, 2026, the stock experienced a significant dip, trending down by nearly 9% amidst concerns about its long-term energy storage outlook.

Looking at its financials, Energy Vault reported revenues near $203.7 million with a positive gross margin. However, it's currently operating with deeply negative net margins, high debt levels, and negative free cash flow, placing it in a high-risk category for traders. The stock has been in a short-term downtrend, breaking key support regions. Despite these challenges, the underlying technology holds high potential, and its low float means that if sentiment shifts or positive news emerges, a 'short-covering squeeze' or renewed speculative interest could lead to sharp rallies. For instance, reclaiming and holding above the mid-$4s could signal a change in momentum. Investors watching NRGV should be aware of its stressed fundamentals versus its technological promise, keeping a close eye on any new developments that could act as a catalyst for its volatile share price.

SpaceX (SPCX) presents a unique and compelling case for a low-float stock to watch in 2026, though it's not 'low float' in the traditional sense of a small company. Instead, it's characterized by having only 3% to 5% of its total stock float publicly traded, making the available shares incredibly scarce. This scarcity, combined with major recent developments, positions SPCX for potentially explosive moves.

A significant catalyst on the horizon is SpaceX's anticipated inclusion in the Nasdaq 100 index, set for July 7, 2026. This event is expected to trigger substantial index-tracking buys, with analysts projecting around $4.3 billion worth of stock purchases by funds like QQQ. Such a large influx of demand against a very limited public supply could lead to considerable price appreciation. Beyond index inclusion, SpaceX has also reported impressive operational milestones, including Starlink surpassing 10 million subscribers and securing $27.8 billion in AI compute contracts. The company's next earnings announcement on August 6, 2026, will be a critical date, as it also marks the first potential release of insider lockups, which could introduce more shares to the market later in the year. Until then, the supply-demand imbalance due to the low public float and index buying is a key factor to monitor.

ADC Therapeutics SA (ADCT) is a clinical-stage oncology company, meaning its primary focus is on developing new cancer treatments rather than selling established products. These types of companies are often characterized by significant volatility, and ADCT is no exception, exhibiting 'high-beta nature' and 'significant intraday volatility' as recently as May 4, 2026. While a precise float number isn't always the headline for such firms, their smaller market capitalization and reliance on clinical milestones often result in limited publicly traded shares and dramatic price reactions to news.

ADCT is currently pre-profitability, with ongoing losses as it funds the commercialization of its drug Zynlonta and continues pipeline development. The revenue ramp for Zynlonta has been slower than initially projected, impacting its share price. However, the stock has shown resilience, tripling from its 52-week low of $1.22 to trade around $3.68 as of May 4, 2026, though still below its 52-week high of $4.98. Key catalysts for ADCT include accelerating Zynlonta revenue growth, positive clinical data readouts from its pipeline studies, and the potential for partnerships, licensing deals, or even an acquisition by a larger pharmaceutical company. The broader ADC (Antibody-Drug Conjugate) sector has seen considerable M&A activity, which could provide a tailwind for ADCT. Investors should be prepared for continued volatility as the company navigates clinical development and commercialization.